Table 1.
Baseline characteristics of the participants.
| Characteristics | Number (%) |
|---|---|
| Median age (range) | 48.0 (26.0 - 76.0) |
| Male | 24 (40.0) |
| ECOG performance status | |
| 0 | 20 (33.3) |
| 1 | 40 (66.7) |
| Primary site | |
| Acral | 12 (20.0) |
| Trunk | 32 (53.3) |
| Limb | 4 (6.7) |
| Head & Neck | 5 (8.3) |
| Unknown | 7 (11.7) |
| Tumor stage at screening | |
| Unresectable stage IIIc | 2 (3.3) |
| Stage IV | |
| M1a | 10 (16.7) |
| M1b | 14 (23.3) |
| M1c | 31 (51.7) |
| Unknown | 3 (5.0) |
| LDH | |
| ≤ULN | 37 (61.7) |
| >ULN | 23 (38.3) |
| Lines of previous therapies | |
| 0 | 15 (25.0) |
| 1 | 19 (31.7) |
| 2 | 19 (31.7) |
| 3 | 6 (10.0) |
| 4 | 1 (1.7) |
| Previous immunotherapy | |
| PD-1 inhibitor only | 6 (10.0) |
| CTLA-4 inhibitor only | 2 (3.3) |
| Both | 1 (1.7) |
| Number of organ sites with metastasis | |
| 1 | 12 (20.0) |
| 2 | 13 (21.7) |
| ≥3 | 35 (58.3) |
Data are number (%), unless otherwise indicated. ECOG, Eastern Cooperative Oncology Group; CSD, chronically sun-damaged cutaneous melanoma; LDH, lactic dehydrogenase; ULN, upper limit of normal; PD-1, programmed cell death protein-1; CTLA-4, cytotoxic T lymphocyte associate protein-4.